Spironolactone is an aldosterone antagonist indicated for heart failure, hypertension, edema and primary hyperaldosteronism. We supply it to US manufacturers of tablets and oral suspension.
Data from PubChem (CID 5833) and FDA’s substance registry
CAS number
52-01-7
Molecular formula
C24H32O4S
Molecular weight
416.6g/mol
FDA UNII
IUPAC name
S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
InChIKey
LXMSZDCAJNLERA-ZHYRCANASA-N
- Appearance
- Light cream-colored to light tan crystalline powder.
- Solubility
- Practically insoluble in water and soluble in alcohol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Practically insoluble in water. Micronized grades are standard for tablets and oral suspension, so confirm the particle size range.
On the US market
- Reference product
- AldactoneNDA 012151
- Approved ANDAs
- 12 with a marketed product
- Approved forms and strengths
- Tablet 25 mg, 50 mg, 100 mg
- Oral suspension 25 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com